Fluphenazine pharmacokinetics and therapeutic response

Maurice W. Dysken, Javaid I. Javaid, Sidney S. Chang, Charles Schaffer, Agha Shahid, John M. Davis

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCl over a 2-week period. Both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (±SD) was 16.4±13.3 h. We found that concomitant use of benztropin mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalPsychopharmacology
Volume73
Issue number3
DOIs
StatePublished - May 1981

Fingerprint

Fluphenazine
Pharmacokinetics
Mesylates
Therapeutics
Double-Blind Method
Half-Life

Cite this

Dysken, M. W., Javaid, J. I., Chang, S. S., Schaffer, C., Shahid, A., & Davis, J. M. (1981). Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology, 73(3), 205-210. https://doi.org/10.1007/BF00422403

Fluphenazine pharmacokinetics and therapeutic response. / Dysken, Maurice W.; Javaid, Javaid I.; Chang, Sidney S.; Schaffer, Charles; Shahid, Agha; Davis, John M.

In: Psychopharmacology, Vol. 73, No. 3, 05.1981, p. 205-210.

Research output: Contribution to journalArticle

Dysken, MW, Javaid, JI, Chang, SS, Schaffer, C, Shahid, A & Davis, JM 1981, 'Fluphenazine pharmacokinetics and therapeutic response', Psychopharmacology, vol. 73, no. 3, pp. 205-210. https://doi.org/10.1007/BF00422403
Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology. 1981 May;73(3):205-210. https://doi.org/10.1007/BF00422403
Dysken, Maurice W. ; Javaid, Javaid I. ; Chang, Sidney S. ; Schaffer, Charles ; Shahid, Agha ; Davis, John M. / Fluphenazine pharmacokinetics and therapeutic response. In: Psychopharmacology. 1981 ; Vol. 73, No. 3. pp. 205-210.
@article{cbb67cc04f4f4c45a1b1f52898048b4c,
title = "Fluphenazine pharmacokinetics and therapeutic response",
abstract = "We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCl over a 2-week period. Both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (±SD) was 16.4±13.3 h. We found that concomitant use of benztropin mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.",
author = "Dysken, {Maurice W.} and Javaid, {Javaid I.} and Chang, {Sidney S.} and Charles Schaffer and Agha Shahid and Davis, {John M.}",
year = "1981",
month = "5",
doi = "10.1007/BF00422403",
language = "English (US)",
volume = "73",
pages = "205--210",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Fluphenazine pharmacokinetics and therapeutic response

AU - Dysken, Maurice W.

AU - Javaid, Javaid I.

AU - Chang, Sidney S.

AU - Schaffer, Charles

AU - Shahid, Agha

AU - Davis, John M.

PY - 1981/5

Y1 - 1981/5

N2 - We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCl over a 2-week period. Both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (±SD) was 16.4±13.3 h. We found that concomitant use of benztropin mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.

AB - We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCl over a 2-week period. Both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (±SD) was 16.4±13.3 h. We found that concomitant use of benztropin mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.

UR - http://www.scopus.com/inward/record.url?scp=0019449144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019449144&partnerID=8YFLogxK

U2 - 10.1007/BF00422403

DO - 10.1007/BF00422403

M3 - Article

C2 - 6787637

AN - SCOPUS:0019449144

VL - 73

SP - 205

EP - 210

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -